# A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis

> **NCT06808815** · PHASE1 · COMPLETED · sponsor: **DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company** · enrollment: 104 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** DC-806
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06808815
- **Lead sponsor:** DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-22
- **Primary completion:** 2022-08-23
- **Final completion:** 2022-08-23
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2025-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06808815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06808815, "A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06808815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*